ClinicalTrials.gg
Active, not recruitingNCT05809531VALEUpdated Apr 2, 2026

An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

A Phase 3 interventional study of Pegcetacoplan in C3G, IC-MPGN and C3 Glomerulopathy, sponsored by Apellis Pharmaceuticals, Inc.. Active, not recruiting at 47 sites in 15 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-04-02.

Sponsored by Apellis Pharmaceuticals, Inc. (part of Biogen) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Glomerulonephritis, Membranoproliferative with a site in United States — 1 open to participants now, 2 under way, 2 of them phase 3. Glomerulonephritis, Membranoproliferative · United States.

Planned enrollment
3rd of 15
100 · median 13
Started
2023
the only one that year
Phase 3
3 of 15
1 open now
Registered
15th of 15
by date
Lead sponsor
4 of 15
Apellis Pharmaceuticals, Inc.

Among the 15 studies in Glomerulonephritis, Membranoproliferative with a site in United States, this one is the 3rd largest by planned enrollment, is the only one that started in 2023, is one of 3 in phase 3, and was the 15th registered.

Glomerulonephritis, Membranoproliferative

33 studies on the registry are indexed under Glomerulonephritis, Membranoproliferative; 10 are open to participants now.

Browse Glomerulonephritis, Membranoproliferative studies →

Open to participants now

1 of the 15 studies in Glomerulonephritis, Membranoproliferative with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 9 Glomerulonephritis, Membranoproliferative studies recruiting now, 5 set no upper age limit and none stop at 75 or younger; 5 take children under 18; 1 takes healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Glomerulonephritis, Membranoproliferative with a site in United States, or all of them as a file.
02

Study summary

This study is designed as a long-term extension to Study APL2-C3G-310, and is being conducted to establish the long-term safety and efficacy of pegcetacoplan in patients with C3 glomerulopathy (C3G) or immune-complex membranoproliferative glomerulonephritis (IC-MPGN).

03

Conditions studied

  • C3G
  • IC-MPGN
  • C3 Glomerulopathy
  • C3 Glomerulonephritis
  • Complement 3 Glomerulopathy
  • Complement 3 Glomerulopathy (C3G)
  • Complement 3 Glomerulonephritis
  • Dense Deposit Disease
  • DDD
  • Membranoproliferative Glomerulonephritis
  • Membranoproliferative Glomerulonephritis (MPGN)
  • Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completed participation in Study APL2-C3G-310 through the week 52 visit requirements
  • Experienced clinical benefit from pegcetacoplan while participating in the previous trial, in the opinion of the investigator
  • Must remain on a stable regimen for C3G or IC-MPGN treatment according to the requirements of Study APL2-C3G-310
  • Received vaccinations against S pneumoniae, N meningitidis (types A, C, W, Y, and B), and H influenzae (type B) according to the requirements of Study APL2-C3G-310 and agree to receive any additional vaccinations recommended according to ACIP recommendations for adults or children with complement deficiencies and/or immunocompromising conditions or other similar local applicable guidelines
  • Female participants of , defined as any woman who has experienced menarche and who is not permanently sterile or , must have a negative urine pregnancy test at visit 1 and must agree to use protocol-defined methods of for the duration of the study through at least 90 days after receiving the last dose of pegcetacoplan
  • Male participants must agree to use protocol-defined methods of contraception and agree to refrain from donating semen for the duration of the study through at least 90 days after receiving the last dose of pegcetacoplan
  • Participants above the legal age of consent, in accordance with local regulations, must be willing and able to provide . The legally authorized representative of participants under the legal age of consent must be willing and able to provide informed consent; where appropriate, participants under the legal age of consent must also give their assent to participation in the study
  • Willing and able to self-administer pegcetacoplan or have an identified caregiver who can perform the administration

Exclusion criteria

Exclusion Criteria:

  • Female participants who are or are planning to become pregnant or who are currently breastfeeding and are unwilling to discontinue for the duration of the study and for at least 90 days after the final dose of study drug
  • Inability or unwillingness to cooperate with the requirements of the protocol
  • Any condition that, in the opinion of the investigator, creates an undue risk for the participant by participating in the study or is likely to confound interpretation of the study results
  • Evidence of ongoing drug or alcohol abuse or dependence, in the opinion of the investigator
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Pegcetacoplan administered subcutaneously

    Pegcetacoplan administered subcutaneously twice weekly according to protocol defined dosing regimen

    Drug: Pegcetacoplan

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of participants with a reduction in urine protein-to-creatinine ratio (uPCR) of at least 50% from the pretreatment value over time.

    Time frame: 2.5 years

07

Study locations

47 sites
08

References and documents

Publications

  • Vivarelli M, Ariceta G, Borovitz Y, Dixon BP, Greenbaum LA, Licht C, Mastrangelo A, Melhem N, Fujita N, van de Kar NCAJ, Wallace D, Khankin E, Wang Z, Lopez-Lazaro L, Szamosi J, Nester CM. Pegcetacoplan for Adolescents with C3 Glomerulopathy or Primary Immune Complex Membranoproliferative GN: Phase 3 VALIANT Subgroup Analysis. Clin J Am Soc Nephrol. 2026 May 14. doi: 10.2215/CJN.0000001077. Online ahead of print. PubMed 42133432 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2023 (actual). Primary completion is estimated for Jul 2027, 50 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2023
First posted
Apr 12, 2023
StartActual
May 29, 2023
Primary completionEst.
Jul 2027
CompletionEst.
Jul 2027
Last update
Apr 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05809531
Responsible party
Sponsor
First posted
Apr 12, 2023
Start date
May 29, 2023
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Apr 2, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegcetacoplan

Start the discussion